The Limn
Rare Disease Sub-Category White Space: Q1 2026
Rare disease development coverage systematically misses the sub-category layer - therapeutic positions that exist given orphan disease burden data but have no named developer and no active development program. Twenty-four structural gaps identified, each SCE-validated across independent research sources.
24Gaps identified
SCEValidated
81%Convergence score
24Structural findings
What this report contains
- Structural gaps ranked by convergence score and strategic relevance.
- Incumbent portfolio analysis and competitive positioning.
- Entry architecture and market formation signals.
- First-mover window assessment and strategic timing.
- Complete SCE methodology validation and model agreement.
What this report does not contain
- Non-public financial disclosures or contract-level data.
- M&A recommendations or specific teaming advice.
- Methodology internals beyond validation framework.
- Full landscape dossiers for every adjacent vendor.
Sample Signal ONE GAP FROM THIS REPORT. REDACTED. PURCHASE UNLOCKS THE FULL SET.
This report maps structural gaps ranked by analytical convergence score. One sample signal from this report is redacted here. Acquiring this report unlocks the complete gap library with confidence scoring and entry architecture detail.